
PolicyLab

H The Children's Hospital of Philadelphia ARESEARCH INSTITUTE



Ensuring Access to Long Acting Reversible Contraceptives (LARC) for Adolescents

Aletha Y. Akers, MD, MPH, FACOG PolicyLab at The Children's Hospital of Philadelphia


July 9 2015


- Provide evidence that LARCS are SAFE
- **Describe** LARC methods
- Special considerations for use in adolescents
- Policy needs to improve access and utilization

- Bayer Healthcare Pharmaceuticals
- National Institutes of Health
- ' Templeton Foundation
- Center of Excellence, University of Pennsylvania

() The Children's Hospital of Philadelphia | RESEARCH INSTITUTE

- L-Long
- A Acting
- R Reversible
- C Contraceptive






ARC METHODS MOST EFFECTIVE

PolicyLab

 $oldsymbol{eta}$ The Children's Hospital of Philadelphia | RESEARCH INSTITUTE

Effectiveness of Family Planning Methods







U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

CONDOMS SHOULD ALWAYS BE USED TO REDUCE THE RISK OF SEXUALLY TRANSMITTED INFECTIONS.

Other Methods of Contraception

Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. Emergency Contraception: Emergency contraceptive pills or a copper IUD after unprotected intercourse substantially reduces risk of pregnancy.

Adapted from World Health Organization (IWHO) Department of Reproductive Health and Research, Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for health project, Family planning: a global handbook for providers (2011) update). Baltimore, MD, Genera, Switzerland; CCP and WHO; 2011; and Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397—404.

RGANIZATIONS ZOO MU PROMINENT MEDICAL

PolicyLab

OH The Children's Hospital of Philadelphia | RESEARCH INSTITUTE



of Pediatrics American Academy















WOMEN'S HEALTH CARE PHYSICIANS Obstetricians and Gynecologists The American College of

Number 539 • October 2012

(Replaces Committee Opinion No. 392, December 2007)

Committee on Adolescent Health Care

Long-Acting Reversible Contraception Working Group

information should not be construed as dictating an exclusive course of treatment or procedure to be followed. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The

Contraception: Implants and Intrauterine Devices **Adolescents and Long-Acting Reversible**

contraceptives. Adolescents are at high risk of unintended pregnancy and may benefit from increased access to are top-tier contraceptives based on effectiveness, with pregnancy rates of less than 1% per year for perfect implant—are safe and appropriate contraceptive methods for most women and adolescents. The LARC methods use and typical use. These contraceptives have the highest rates of satisfaction and continuation of all reversible ABSTRACT: Long-acting reversible contraception (LARC)—intrauterine devices and the contraceptive


DURING TEEN YEARS COMMON

PolicyLab

94 The Children's Hospital of Philadelphia | RESEARCH INSTITUTE

Teen Sexual Activity

Adolescence is a time of rapid change.




www.guttmacher.org

AMONG TEENS, BUT A BIG IMPACT


PolicyLab

CH The Children's Hospital of Philadelphia | | RESEARCH INSTITUTE

Proportion of Pregnancies among U.S. Women by Age



Proportion of <u>Unintended</u> Pregnancies among U.S. Women by Age



SOURCES: CDC/NCHS, National Vital Statistics System and National Survey of Family Growth; CDC, Abortion Surveillance System; and Guttmacher Institute.

Finer, AJPH, 2014

- Contraception
- General population
- Postpartum
- Postabortal
- Emergency contraception
- Menstrual problems
- Heavy menstrual flow
- Dysmenorrhea
- When estrogen medically contraindicated

Funded by anonymous foundation

CONTRACEPTIVE

CHQICE PROJECT

- Provided no-cost contraception to reproductive age women in St. Louis
- LARC Of the 1,404 teen participants 72% chose a
- Pregnancy rate 34.0 per 1,000 vs national average of 158.5 per 1,000
- Abortion rate was 9.7 per 1,000 vs national average of 41.5 per 1,000 teens


- Teen abortion rate fell 35% between 2009 and 2012
- associated with teen births State saved \$42.5 million in health expenditures
- postpartum IUD Teens 5X more likely to be pregnant again one year later if they did not receive an immediate

Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012;206:481.e1-7.

ARC?

(1) The Children's Hospital of Philadelphia : RESEARCH INSTITUTE

Percent of Adolescents Who Used Each Birth Control Method at Last Sex*





^{*} Among the 34% of high school students who have been sexually active in the past 3 months

OH The Children's Hospital of Philadelphia" | RESEARCH INSTITUTE

- Intrauterine Contraception
- Non-Horomonal
- Paragard (1988)
- Hormonal
- Mirena IUS (2000)
- Skyla (2013)
- Liletta (2015)

- Subdermal Hormonal Implant
- Nexplanon (2006)







20 (1) (2) (2) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4				women
×	×		×	Nulliparous
			X (≤72 hours unprotected sex)	Emergency contraception
	×	×		Menorrhagia
(3 years)	X (3 years)	X (5-7 years)	X (10-12 years)	Contraception
Nexplanon	Skyla	Mirena	Paragard	Indication


8									
н							6		
и							ь		
в							Ħ	ı	ı
ø							Ħ		
Ŕ									
ø									
ĸ				ď					
æ				ą					
鎾									
a				ż					
а				3	۳	3		٩	
闘				'n	я	ř	۹	Ľ	١
				ı	L	ı	ú	P	1
				L	٠	e		٩	
							m		
9				ľ		1	=	3	
	g								
					ø	8	П		
					ø	1	и		
a					ä	7	и		
					7	٩	薆		
					9	ů,			
					d		а		
					2		9		
		N			ä	4	ø		
					2	¢	ø		
					ø	4	3		
					ä				
				ś	ď,	9			
				Ŕ		4			
e				Ľ	á	á			
ø	ğ			ø	ď	d	뼥		
				ø	ø	j	ø		
				ř	é	í	d		
				ľ	á				
			μ	E	4				
				K					
				ŀ	ė		ŝ		
	ĕ			Ľ	2				
				Ľ	I				
				e	3				
			S	8	ÿ	۹			
				H	2	Ħ	8		
				G	r	ē,			
					2	ď			
				Ľ	8	e	Ζ		
	ĸ			Б	b	ä	а		
				þ	3				
				Ľ	2				
				ß	а		9		
			2	5	ä				
	ε			١	2	3			
				E	2				
				5	d				
				ú	d				
				3					
				Ė	Ż	á			
				F	ï		ø		
				И	ų				
				ø	8				
				g	ź				
9				Ņ	ņ	ĕ			
				4	DUNING THE PROPERTY OF THE PARTY OF THE PART				
				þ	ð	į			
			ă	ø	d				
				ä	z				
				ú	١				
			ġ	d	ú				
				Ħ	۹				
				ď				g	
				í	9				
				ŕ	á				
			ø	ÿ	ij				
			Ľ	9	ū				
ø			e	ø	d				
繭		ø	þ	ø	ч				
		ø		ø	Ŋ				
	S		b	ø	ų				Ñ
			ľ	e	¢				
				ø	H				
			Ė	ä	d				
8			ß	ű	1				
ø				ø	ø				
			S						
							ø		

Rare Side effects	Common Side Spotting, amenorrhea effects	Notable features Also marketed for treatment of heavy menstrual bleeding	Year method was FDA approved	Failure rate in practice 0.2%	Effective time Up to five years	Active ingredient Hormonal (levonorgestrel)	Mirena		LONG-ACTING REVERSIBLE CONTRACEPTION
Expulsion, infection, perforation	Increase menstrual bleeding and cramps	Marketed as the most effective reversible method that is hormone-free	1984	0.8%	Up to 10 years	Copper-releasing	ParaGard	INTRAUTERINE DEVICE (IUD)	CONTRACEPTION
Expulsion, infection, perforation, , hormone effect	Spotting	Marketed specifically for women who have not given birth	2013	0.2%	Up to three years	Hormonal (levonorgestrel)	Skyla	E (IUD)	
Deep placement, infection	Irregular bleeding of variable duration	Equipped with a pre loaded applicator designed to ease insertion	2011	0.05%	Up to three years	Hormonal (etonogestrel)	Nexplanon	IMPLANT	


- medication reservoir Vinyl-based frame with
- Duration 3 year
- Mechanism
- Inhibit ovulation and thicken cervical mucus
- Rapid onset of action and rapidly reversible
- Side effects: pain, redness, swelling







H. The Children's Hospital of Philadelphia" | RESEARCH INSTITUTE



Provider Considerations

Counseling Inse

ISSUES

LARC Knowledge

Insertion Skills

Post-insertion Management

SOLUTIONS


Education Opportunities

Training

Training

Education Opportunities

(1) The Children's Hospital of Philadelphia | RESEARCH INSTITUTE





Confidentiality in EMR

Discrepancies in

ISSUES

Institutional Contracts
Fix discrepancies for reimbursement for LARC services


SOLUTIONS

Fix Confidentiality Issues in EOBs

Approval for insertions for nonOBGYNs


PolicyLab

H The Children's Hospital of Philadelphia! RESEARCH INSTITUTE






Health Providers







Improve provider knowledge about indications for LARC use








- Fix confidentiality issues due to EOBs
- Fix discrepancies in facilities' contracts for reimbursement for LARC services
- Address high rates of service denials
- time & complexity of LARC services adolescent services due to increased Improve reimbursement for




H The Children's Hospital of Philadelphia | RESEARCH INSTITUTE

@H The Children's Hospital of Philadelphia" | RESEARCH INSTITUTE


- Approved for up to 10 years
- Mechanism
- Prevent fertilization
- Reduce sperm action and egg maturation
- Inhospitable environment in uterus
- Side effects: heavy periods and cramps



- Duration 5-7 years
- Location hormones = minimal side effects
- Mechmanism
- Thicken cervical mucous
- Inhibition of sperm action
- Inhospitable uterine environment
- Side effects
- Common: pain with insertion, cramps, spotting, amenorrhea
- Rare: mood change, acne, infection, expulsion, perforation



- T-shaped frame with medication reservoir
- Duration 3 years
- Mechanism, side effects, failure rate similar to Mirena



•				
•				
	97			
			*	
			<i>y</i>	
		267		